Evaluation of prostaglandin E1 for prevention of respiratory failure in high risk trauma patients

A prospective clinical trial and correlation with plasma suppressive factors for neutrophil activation

M. J. Vassar, M. P. Fletcher, C. A. Perry, James W Holcroft

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A group of 48 critically injured patients were entered into a prospective, double-blind, placebocontrolled trial to evaluate the efficacy of early infusion of PGE1 for reducing the incidence of severe respiratory failure and mortality. Secondary assessments examined the effects of the PGE1 infusion on plasma mediated suppression of PMN superoxide production and loss of PMN granule enzyme content. The incidence of severe respiratory failure was lower in the PGE1 group - 13% versus 32%, but this did not reach significance. The overall morality was equivalent between the two groups - 26% (PGE1) versus 28% (placebo). The suppressive activity of the patient plasma was assayed by measurement of normal PMN superoxide production relative to normal control plasma (ratio P:C). The baseline ratio P:C was 62 ± 5% in the PGE1 group versus 60 ± 5% in the placebo group. The day 1 plasma samples showed significant reversal of plasma suppressive activity in the PGE1 group - ratio P:C 88 ± 5% versus 67 ± 5% in the placebo group (P < 0.02). In patients who received the full 7 days of infusion, the plasma suppressive activity remained significantly diminished in the PGE1 group - ratio P:C 77 ± 4% versus 61 ± 5% (P < 0.04). The baseline lysozyme content of patient PMN's relative to that of normal control PMNs (ratio P:C) was 119 ± 14% in the PGE1 group. A significant loss of lysozyme content was observed in the PGE1 group on day 1 of the infusion - ratio P:C 79 ± 8% (P < 0.03), and was associated with a reduction in the plasma suppressive activity. Although no significant clinical benefit could be attributed to the PGE1 infusion, these studies indicate that infusion of PGE1 was associated with attenuated production of post traumatic plasma suppressive factors of PMN activation.

Original languageEnglish (US)
Pages (from-to)223-231
Number of pages9
JournalProstaglandins, Leukotrienes and Essential Fatty Acids
Volume44
Issue number4
DOIs
StatePublished - 1991

Fingerprint

Alprostadil
Interleukin-8
Respiratory Insufficiency
Clinical Trials
Plasmas
Wounds and Injuries
Placebos
Muramidase
Superoxides
Thermodynamic properties
Incidence
Chemical activation

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{ea4d17d4d7864c1b8a56f8413702101c,
title = "Evaluation of prostaglandin E1 for prevention of respiratory failure in high risk trauma patients: A prospective clinical trial and correlation with plasma suppressive factors for neutrophil activation",
abstract = "A group of 48 critically injured patients were entered into a prospective, double-blind, placebocontrolled trial to evaluate the efficacy of early infusion of PGE1 for reducing the incidence of severe respiratory failure and mortality. Secondary assessments examined the effects of the PGE1 infusion on plasma mediated suppression of PMN superoxide production and loss of PMN granule enzyme content. The incidence of severe respiratory failure was lower in the PGE1 group - 13{\%} versus 32{\%}, but this did not reach significance. The overall morality was equivalent between the two groups - 26{\%} (PGE1) versus 28{\%} (placebo). The suppressive activity of the patient plasma was assayed by measurement of normal PMN superoxide production relative to normal control plasma (ratio P:C). The baseline ratio P:C was 62 ± 5{\%} in the PGE1 group versus 60 ± 5{\%} in the placebo group. The day 1 plasma samples showed significant reversal of plasma suppressive activity in the PGE1 group - ratio P:C 88 ± 5{\%} versus 67 ± 5{\%} in the placebo group (P < 0.02). In patients who received the full 7 days of infusion, the plasma suppressive activity remained significantly diminished in the PGE1 group - ratio P:C 77 ± 4{\%} versus 61 ± 5{\%} (P < 0.04). The baseline lysozyme content of patient PMN's relative to that of normal control PMNs (ratio P:C) was 119 ± 14{\%} in the PGE1 group. A significant loss of lysozyme content was observed in the PGE1 group on day 1 of the infusion - ratio P:C 79 ± 8{\%} (P < 0.03), and was associated with a reduction in the plasma suppressive activity. Although no significant clinical benefit could be attributed to the PGE1 infusion, these studies indicate that infusion of PGE1 was associated with attenuated production of post traumatic plasma suppressive factors of PMN activation.",
author = "Vassar, {M. J.} and Fletcher, {M. P.} and Perry, {C. A.} and Holcroft, {James W}",
year = "1991",
doi = "10.1016/0952-3278(91)90021-V",
language = "English (US)",
volume = "44",
pages = "223--231",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Evaluation of prostaglandin E1 for prevention of respiratory failure in high risk trauma patients

T2 - A prospective clinical trial and correlation with plasma suppressive factors for neutrophil activation

AU - Vassar, M. J.

AU - Fletcher, M. P.

AU - Perry, C. A.

AU - Holcroft, James W

PY - 1991

Y1 - 1991

N2 - A group of 48 critically injured patients were entered into a prospective, double-blind, placebocontrolled trial to evaluate the efficacy of early infusion of PGE1 for reducing the incidence of severe respiratory failure and mortality. Secondary assessments examined the effects of the PGE1 infusion on plasma mediated suppression of PMN superoxide production and loss of PMN granule enzyme content. The incidence of severe respiratory failure was lower in the PGE1 group - 13% versus 32%, but this did not reach significance. The overall morality was equivalent between the two groups - 26% (PGE1) versus 28% (placebo). The suppressive activity of the patient plasma was assayed by measurement of normal PMN superoxide production relative to normal control plasma (ratio P:C). The baseline ratio P:C was 62 ± 5% in the PGE1 group versus 60 ± 5% in the placebo group. The day 1 plasma samples showed significant reversal of plasma suppressive activity in the PGE1 group - ratio P:C 88 ± 5% versus 67 ± 5% in the placebo group (P < 0.02). In patients who received the full 7 days of infusion, the plasma suppressive activity remained significantly diminished in the PGE1 group - ratio P:C 77 ± 4% versus 61 ± 5% (P < 0.04). The baseline lysozyme content of patient PMN's relative to that of normal control PMNs (ratio P:C) was 119 ± 14% in the PGE1 group. A significant loss of lysozyme content was observed in the PGE1 group on day 1 of the infusion - ratio P:C 79 ± 8% (P < 0.03), and was associated with a reduction in the plasma suppressive activity. Although no significant clinical benefit could be attributed to the PGE1 infusion, these studies indicate that infusion of PGE1 was associated with attenuated production of post traumatic plasma suppressive factors of PMN activation.

AB - A group of 48 critically injured patients were entered into a prospective, double-blind, placebocontrolled trial to evaluate the efficacy of early infusion of PGE1 for reducing the incidence of severe respiratory failure and mortality. Secondary assessments examined the effects of the PGE1 infusion on plasma mediated suppression of PMN superoxide production and loss of PMN granule enzyme content. The incidence of severe respiratory failure was lower in the PGE1 group - 13% versus 32%, but this did not reach significance. The overall morality was equivalent between the two groups - 26% (PGE1) versus 28% (placebo). The suppressive activity of the patient plasma was assayed by measurement of normal PMN superoxide production relative to normal control plasma (ratio P:C). The baseline ratio P:C was 62 ± 5% in the PGE1 group versus 60 ± 5% in the placebo group. The day 1 plasma samples showed significant reversal of plasma suppressive activity in the PGE1 group - ratio P:C 88 ± 5% versus 67 ± 5% in the placebo group (P < 0.02). In patients who received the full 7 days of infusion, the plasma suppressive activity remained significantly diminished in the PGE1 group - ratio P:C 77 ± 4% versus 61 ± 5% (P < 0.04). The baseline lysozyme content of patient PMN's relative to that of normal control PMNs (ratio P:C) was 119 ± 14% in the PGE1 group. A significant loss of lysozyme content was observed in the PGE1 group on day 1 of the infusion - ratio P:C 79 ± 8% (P < 0.03), and was associated with a reduction in the plasma suppressive activity. Although no significant clinical benefit could be attributed to the PGE1 infusion, these studies indicate that infusion of PGE1 was associated with attenuated production of post traumatic plasma suppressive factors of PMN activation.

UR - http://www.scopus.com/inward/record.url?scp=0025918605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025918605&partnerID=8YFLogxK

U2 - 10.1016/0952-3278(91)90021-V

DO - 10.1016/0952-3278(91)90021-V

M3 - Article

VL - 44

SP - 223

EP - 231

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

IS - 4

ER -